 - Determine the incidence of acute graft-vs-host disease GVHD requiring therapy in patients with myelodysplastic syndromes or myeloproliferative disorders treated with busulfan, cyclophosphamide, and anti-thymocyte globulin prior to transplantation with filgrastim G-CSF-mobilized peripheral blood stem cells or bone marrow from related or unrelated donors. 